Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05600387
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05600387
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05600387. Randomized; no masking; primary purpose treatment. Start 2022-11-05 (actual); primary completion 2024-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Condition
- Heart Failure
- Condition
- Heart Failure With Mid Range Ejection Fraction
- Intervention (Drug)
- Empagliflozin 10 MG
- Lead sponsor
- Zhijun Sun
Record details
- Record id
cardio:ct-nct05600387- Content hash
7e9746780ad066640877b3b57f12f603e7480c98c0c2200fbca63886a13b3062